[1]
Gorman, A.M. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J. Cell. Mol. Med., 2008, 12(6a), 2263-2280.
[2]
Ferrer, I.; Lopez-Gonzalez, I.; Carmona, M.; Arregui, L.; Dalfo, E.; Torrejon-Escribano, B.; Diehl, R.; Kovacs, G.G. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J. Neuropathol. Exp. Neurol., 2014, 73(1), 81-97.
[3]
Cheng, L.; Alexander, R.E.; Maclennan, G.T.; Cummings, O.W.; Montironi, R.; Lopez-Beltran, A.; Cramer, H.M.; Davidson, D.D.; Zhang, S. Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol., 2012, 25(3), 347-369.
[4]
Korpanty, G.J.; Graham, D.M.; Vincent, M.D.; Leighl, N.B. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front. Oncol., 2014, 4, 204.
[5]
Mall, M.A.; Galietta, L.J. Targeting ion channels in cystic fibrosis. J. Cyst. Fibros., 2015, 14(5), 561-570.
[6]
Hoffman, L.R.; Ramsey, B.W. Cystic fibrosis therapeutics: the road ahead. Chest, 2013, 143(1), 207-213.
[7]
Welsh, M.J.; Smith, A.E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell, 1993, 73(7), 1251-1254.
[8]
Bompadre, S.G.; Sohma, Y.; Li, M.; Hwang, T.C. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J. Gen. Physiol., 2007, 129(4), 285-298.
[9]
Armstrong, R.A. On the ‘classification’ of neurodegenerative disorders: discrete entities, overlap or continuum? Folia neuropathologica / association of polish neuropathologists and medical research centre. Polish Acad. Sci., 2012, 50(3), 201-208.
[10]
Williams-Gray, C.H.; Foltynie, T.; Lewis, S.J.; Barker, R.A. Cognitive deficits and psychosis in Parkinson’s disease: a review of pathophysiology and therapeutic options. CNS Drugs, 2006, 20(6), 477-505.
[11]
Paulsen, J.S. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr. Neurol. Neurosci. Rep., 2011, 11(5), 474-483.
[12]
Cairns, N.J.; Bigio, E.H.; Mackenzie, I.R.; Neumann, M.; Lee, V.M.; Hatanpaa, K.J.; White, C.L., III; Schneider, J.A.; Grinberg, L.T.; Halliday, G.; Duyckaerts, C.; Lowe, J.S.; Holm, I.E.; Tolnay, M.; Okamoto, K.; Yokoo, H.; Murayama, S.; Woulfe, J.; Munoz, D.G.; Dickson, D.W.; Ince, P.G.; Trojanowski, J.Q.; Mann, D.M. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol., 2007, 114(1), 5-22.
[13]
Mackenzie, I.R.; Rademakers, R.; Neumann, M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol., 2010, 9(10), 995-1007.
[14]
Lei, P.; Ayton, S.; Finkelstein, D.I.; Adlard, P.A.; Masters, C.L.; Bush, A.I. Tau protein: relevance to Parkinson’s disease. Int. J. Biochem. Cell Biol., 2010, 42(11), 1775-1778.
[15]
Klunemann, H.H.; Fronhofer, W.; Wurster, H.; Fischer, W.; Ibach, B.; Klein, H.E. Alzheimer’s second patient: Johann F. and his family. Ann. Neurol., 2002, 52(4), 520-523.
[16]
Villemagne, V.L.; Pike, K.E.; Chetelat, G.; Ellis, K.A.; Mulligan, R.S.; Bourgeat, P.; Ackermann, U.; Jones, G.; Szoeke, C.; Salvado, O.; Martins, R.; O’Keefe, G.; Mathis, C.A.; Klunk, W.E.; Ames, D.; Masters, C.L.; Rowe, C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol., 2011, 69(1), 181-192.
[17]
Johnson, K.A.; Minoshima, S.; Bohnen, N.I.; Donohoe, K.J.; Foster, N.L.; Herscovitch, P.; Karlawish, J.H.; Rowe, C.C.; Carrillo, M.C.; Hartley, D.M.; Hedrick, S.; Pappas, V.; Thies, W.H. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement., 2013, 9(1), e-1-e-16.
[18]
Ching, A.S.C.; Kuhnast, B.; Damont, A.; Roeda, D.; Tavitian, B.; Dollé, F. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging, 2012, 3(1), 111-119.
[19]
Cagnin, A.; Brooks, D.J.; Kennedy, A.M.; Gunn, R.N.; Myers, R.; Turkheimer, F.E.; Jones, T.; Banati, R.B. In-vivo measurement of activated microglia in dementia. Lancet (London, England), 2001, 358(9280), 461-467.
[20]
Politis, M.; Su, P.; Piccini, P. Imaging of microglia in patients with neurodegenerative disorders. Front. Pharmacol., 2012, 3, 96.
[21]
Imamura, K.; Hishikawa, N.; Sawada, M.; Nagatsu, T.; Yoshida, M.; Hashizume, Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol., 2003, 106(6), 518-526.
[22]
Sanchez-Guajardo, V.; Febbraro, F.; Kirik, D.; Romero-Ramos, M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS One, 2010, 5(1)e8784
[23]
Bartels, A.L.; Willemsen, A.T.; Doorduin, J.; de Vries, E.F.; Dierckx, R.A.; Leenders, K.L. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease? Parkinsonism Relat. Disord., 2010, 16(1), 57-59.
[24]
Gerhard, A.; Trender-Gerhard, I.; Turkheimer, F.; Quinn, N.P.; Bhatia, K.P.; Brooks, D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov. Disord., 2006, 21(1), 89-93.
[25]
Politis, M.; Pavese, N.; Tai, Y.F.; Tabrizi, S.J.; Barker, R.A.; Piccini, P. Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain, 2008, 131(Pt 11), 2860-2869.
[26]
Politis, M.; Pavese, N.; Tai, Y.F.; Kiferle, L.; Mason, S.L.; Brooks, D.J.; Tabrizi, S.J.; Barker, R.A.; Piccini, P. Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum. Brain Mapp., 2011, 32(2), 258-270.
[27]
Gerhard, A.; Banati, R.B.; Goerres, G.B.; Cagnin, A.; Myers, R.; Gunn, R.N.; Turkheimer, F.; Good, C.D.; Mathias, C.J.; Quinn, N.; Schwarz, J.; Brooks, D.J. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology, 2003, 61(5), 686-689.
[28]
Gerhard, A.; Watts, J.; Trender-Gerhard, I.; Turkheimer, F.; Banati, R.B.; Bhatia, K.; Brooks, D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov. Disord., 2004, 19(10), 1221-1226.
[29]
Banati, R.B.; Newcombe, J.; Gunn, R.N.; Cagnin, A.; Turkheimer, F.; Heppner, F.; Price, G.; Wegner, F.; Giovannoni, G.; Miller, D.H.; Perkin, G.D.; Smith, T.; Hewson, A.K.; Bydder, G.; Kreutzberg, G.W.; Jones, T.; Cuzner, M.L.; Myers, R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain, 2000, 123(Pt 11), 2321-2337.
[30]
Hardy, J.; Orr, H. The genetics of neurodegenerative diseases. J. Neurochem., 2006, 97(6), 1690-1699.
[31]
Bettens, K.; Sleegers, K.; Van Broeckhoven, C. Genetic insights in Alzheimer’s disease. Lancet Neurol., 2013, 12(1), 92-104.
[32]
Farrer, L.A.; Cupples, L.; Haines, J.L. Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease: A meta-analysis. JAMA, 1997, 278(16), 1349-1356.
[33]
Lambert, J-C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellenguez, C.; Jun, G.; DeStefano, A.L.; Bis, J.C.; Beecham, G.W.; Grenier-Boley, B.; Russo, G.; Thornton-Wells, T.A.; Jones, N.; Smith, A.V.; Chouraki, V.; Thomas, C.; Ikram, M.A.; Zelenika, D.; Vardarajan, B.N.; Kamatani, Y.; Lin, C-F.; Gerrish, A.; Schmidt, H.; Kunkle, B.; Dunstan, M.L.; Ruiz, A.; Bihoreau, M-T.; Choi, S-H.; Reitz, C.; Pasquier, F.; Hollingworth, P.; Ramirez, A.; Hanon, O.; Fitzpatrick, A.L.; Buxbaum, J.D.; Campion, D.; Crane, P.K.; Baldwin, C.; Becker, T.; Gudnason, V.; Cruchaga, C.; Craig, D.; Amin, N.; Berr, C.; Lopez, O.L.; De Jager, P.L.; Deramecourt, V.; Johnston, J.A.; Evans, D.; Lovestone, S.; Letenneur, L.; Moron, F.J.; Rubinsztein, D.C.; Eiriksdottir, G.; Sleegers, K.; Goate, A.M.; Fievet, N.; Huentelman, M.J.; Gill, M.; Brown, K.; Kamboh, M.I.; Keller, L.; Barberger-Gateau, P.; McGuinness, B.; Larson, E.B.; Green, R.; Myers, A.J.; Dufouil, C.; Todd, S.; Wallon, D.; Love, S.; Rogaeva, E.; Gallacher, J.; St George-Hyslop, P.; Clarimon, J.; Lleo, A.; Bayer, A.; Tsuang, D.W.; Yu, L.; Tsolaki, M.; Bossu, P.; Spalletta, G.; Proitsi, P.; Collinge, J.; Sorbi, S.; Sanchez-Garcia, F.; Fox, N.C.; Hardy, J.; Naranjo, M.C.D.; Bosco, P.; Clarke, R.; Brayne, C.; Galimberti, D.; Mancuso, M.; Matthews, F. European Alzheimer’s Disease, I.; Genetic; Environmental Risk in Alzheimer’s, D.; Alzheimer’s Disease Genetic, C.; Cohorts for, H.; Aging Research in Genomic, E.; Moebus, S.; Mecocci, P.; Del Zompo, M.; Maier, W.; Hampel, H.; Pilotto, A.; Bullido, M.; Panza, F.; Caffarra, P.; Nacmias, B.; Gilbert, J.R.; Mayhaus, M.; Lannfelt, L.; Hakonarson, H.; Pichler, S.; Carrasquillo, M.M.; Ingelsson, M.; Beekly, D.; Alvarez, V.; Zou, F.; Valladares, O.; Younkin, S.G.; Coto, E.; Hamilton-Nelson, K.L.; Gu, W.; Razquin, C.; Pastor, P.; Mateo, I.; Owen, M.J.; Faber, K.M.; Jonsson, P.V.; Combarros, O.; O’Donovan, M.C.; Cantwell, L.B.; Soininen, H.; Blacker, D.; Mead, S.; Mosley Jr, T.H.; Bennett, D.A.; Harris, T.B.; Fratiglioni, L.; Holmes, C.; de Bruijn, R.F.A.G.; Passmore, P.; Montine, T.J.; Bettens, K.; Rotter, J.I.; Brice, A.; Morgan, K.; Foroud, T.M.; Kukull, W.A.; Hannequin, D.; Powell, J.F.; Nalls, M.A.; Ritchie, K.; Lunetta, K.L.; Kauwe, J.S.K.; Boerwinkle, E.; Riemenschneider, M.; Boada, M.; Hiltunen, M.; Martin, E.R.; Schmidt, R.; Rujescu, D.; Wang, L.-S.; Dartigues, J.-F.; Mayeux, R.; Tzourio, C.; Hofman, A.; Nothen, M.M.; Graff, C.; Psaty, B.M.; Jones, L.; Haines, J.L.; Holmans, P.A.; Lathrop, M.; Pericak-Vance, M.A.; Launer, L.J.; Farrer, L.A.; van Duijn, C.M.; Van Broeckhoven, C.; Moskvina, V.; Seshadri, S.; Williams, J.; Schellenberg, G.D.; Amouyel, P., Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet., 2013, 45(12), 1452-1458.
[34]
Guerreiro, R.; Wojtas, A.; Bras, J.; Carrasquillo, M.; Rogaeva, E.; Majounie, E.; Cruchaga, C.; Sassi, C.; Kauwe, J.S.K.; Younkin, S.; Hazrati, L.; Collinge, J.; Pocock, J.; Lashley, T.; Williams, J.; Lambert, J.C.; Amouyel, P.; Goate, A.; Rademakers, R.; Morgan, K.; Powell, J.; St George-Hyslop, P.; Singleton, A.; Hardy, J. Alzheimer genetic anal, G., TREM2 variants in Alzheimer’s disease. N. Engl. J. Med., 2013, 368(2), 117-127.
[35]
Jonsson, T.; Stefansson, H.; Steinberg, S.; Jonsdottir, I.; Jonsson, P.V.; Snaedal, J.; Bjornsson, S.; Huttenlocher, J.; Levey, A.I.; Lah, J.J.; Rujescu, D.; Hampel, H.; Giegling, I.; Andreassen, O.A.; Engedal, K.; Ulstein, I.; Djurovic, S.; Ibrahim-Verbaas, C.; Hofman, A.; Ikram, M.A.; van Duijn, C.M.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med., 2013, 368(2), 107-116.
[36]
Finelli, D.; Rollinson, S.; Harris, J.; Jones, M.; Richardson, A.; Gerhard, A.; Snowden, J.; Mann, D.; Pickering-Brown, S. TREM2 analysis and increased risk of Alzheimer’s disease. Neurobiol. Aging, 2015, 36(1), 546.e549-546.e513.
[37]
Lu, Y.; Liu, W.; Wang, X. TREM2 variants and risk of Alzheimer’s disease: a meta-analysis. Neurol. Sci., 2015, 36(10), 1881-1888.
[38]
Jin, S.C.; Carrasquillo, M.M.; Benitez, B.A.; Skorupa, T.; Carrell, D.; Patel, D.; Lincoln, S.; Krishnan, S.; Kachadoorian, M.; Reitz, C.; Mayeux, R.; Wingo, T.S.; Lah, J.J.; Levey, A.I.; Murrell, J.; Hendrie, H.; Foroud, T.; Graff-Radford, N.R.; Goate, A.M.; Cruchaga, C.; Ertekin-Taner, N. TREM2 is associated with increased risk for Alzheimer’s disease in African Americans. Mol. Neurodegener., 2015, 10, 19.
[39]
Lill, C.M.; Rengmark, A.; Pihlstrøm, L.; Fogh, I.; Shatunov, A.; Sleiman, P.M.; Wang, L.S.; Liu, T.; Lassen, C.F.; Meissner, E.; Alexopoulos, P.; Calvo, A.; Chio, A.; Dizdar, N.; Faltraco, F.; Forsgren, L.; Kirchheiner, J.; Kurz, A.; Larsen, J.P.; Liebsch, M.; Linder, J.; Morrison, K.E.; Nissbrandt, H.; Otto, M.; Pahnke, J.; Partch, A.; Restagno, G.; Rujescu, D.; Schnack, C.; Shaw, C.E.; Shaw, P.J.; Tumani, H.; Tysnes, O.B.; Valladares, O.; Silani, V.; van den Berg, L.H.; van Rheenen, W.; Veldink, J.H.; Lindenberger, U.; Steinhagen-Thiessen, E.; Teipel, S.; Perneczky, R.; Hakonarson, H.; Hampel, H.; von Arnim, C.A.F.; Olsen, J.H.; Van Deerlin, V.M.; Al-Chalabi, A.; Toft, M.; Ritz, B.; Bertram, L. The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimers Dement., 2015, 11(12), 1407-1416.
[40]
Jonsson, T.; Atwal, J.K.; Steinberg, S.; Snaedal, J.; Jonsson, P.V.; Bjornsson, S.; Stefansson, H.; Sulem, P.; Gudbjartsson, D.; Maloney, J.; Hoyte, K.; Gustafson, A.; Liu, Y.; Lu, Y.; Bhangale, T.; Graham, R.R.; Huttenlocher, J.; Bjornsdottir, G.; Andreassen, O.A.; Jonsson, E.G.; Palotie, A.; Behrens, T.W.; Magnusson, O.T.; Kong, A.; Thorsteinsdottir, U.; Watts, R.J.; Stefansson, K. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature, 2012, 488(7409), 96-99.
[41]
Carrell, R.W.; Lomas, D.A. Conformational disease. Lancet, 1997, 350(9071), 134-138.
[42]
Kovacs, G.G. Molecular pathological classification of neurodegenerative diseases: Turning towards precision medicine. Int. J. Mol. Sci., 2016, 17(2), 189.
[43]
Kovacs, G.G. Current concepts of neurodegenerative diseases. Eur. Med. J. Neurol., 2014, 1, 78-86.
[44]
Neumann, M.; Bentmann, E.; Dormann, D.; Jawaid, A.; DeJesus-Hernandez, M.; Ansorge, O.; Roeber, S.; Kretzschmar, H.A.; Munoz, D.G.; Kusaka, H.; Yokota, O.; Ang, L.C.; Bilbao, J.; Rademakers, R.; Haass, C.; Mackenzie, I.R. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain, 2011, 134(Pt 9), 2595-2609.
[45]
Valera, E.; Spencer, B.; Masliah, E. Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics, 2016, 13(1), 179-189.
[46]
Panza, F.; Solfrizzi, V.; Imbimbo, B.P.; Giannini, M.; Santamato, A.; Seripa, D.; Logroscino, G. Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Rev. Neurother., 2014, 14(9), 973-986.
[47]
Farlow, M.; Arnold, S.E.; van Dyck, C.H.; Aisen, P.S.; Snider, B.J.; Porsteinsson, A.P.; Friedrich, S.; Dean, R.A.; Gonzales, C.; Sethuraman, G.; DeMattos, R.B.; Mohs, R.; Paul, S.M.; Siemers, E.R. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement., 2012, 8(4), 261-271.
[48]
Giuliani, D.; Zaffe, D.; Ottani, A.; Spaccapelo, L.; Galantucci, M.; Minutoli, L.; Bitto, A.; Irrera, N.; Contri, M.; Altavilla, D.; Botticelli, A.R.; Squadrito, F.; Guarini, S. Treatment of cerebral ischemia with melanocortins acting at MC4 receptors induces marked neurogenesis and long-lasting functional recovery. Acta Neuropathol., 2011, 122(4), 443-453.
[49]
Giuliani, D.; Bitto, A.; Galantucci, M.; Zaffe, D.; Ottani, A.; Irrera, N.; Neri, L.; Cavallini, G.M.; Altavilla, D.; Botticelli, A.R.; Squadrito, F.; Guarini, S. Melanocortins protect against progression of Alzheimer’s disease in triple-transgenic mice by targeting multiple pathophysiological pathways. Neurobiol. Aging, 2014, 35(3), 537-547.
[50]
Giuliani, D.; Ottani, A.; Minutoli, L.; Stefano, V.D.; Galantucci, M.; Bitto, A.; Zaffe, D.; Altavilla, D.; Botticelli, A.R.; Squadrito, F.; Guarini, S. Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268. Brain Behav. Immun., 2009, 23(6), 844-850.
[51]
Giuliani, D.; Ottani, A.; Neri, L.; Zaffe, D.; Grieco, P.; Jochem, J.; Cavallini, G.M.; Catania, A.; Guarini, S. Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: therapeutic perspectives. Prog. Neurobiol., 2017, 148, 40-56.
